Home Your basket
• Validation of a self asse...
   Price 10.50 €
• Botulinum toxin in the lo...
   Price 14.00 €
• Tonsillitis tuberculous s...
   Price 8.50 €
• The pedicled musculo-cuta...
   Price 8.50 €
• Management of peritonsill...
   Price 5.50 €
• Treatment of children wit...
   Price 8.50 €
• Neuroplasticity in the au...
   Price 10.50 €
• Laryngeal tuberculosis....
   Price 8.50 €
• Progressive cochleo-vesti...
   Price 5.50 €
• Association of thyroid he...
   Price 12.50 €
• Assumptions in surgical t...
   Price 8.50 €
• Parathyroid carcinoma: di...
   Price 5.50 €
• Notes on voice and speech...
   Price 8.50 €
• Vestibular disorders in B...
   Price 14.00 €
• Facial nerve monitoring d...
   Price 12.50 €
• Early education for child...
   Price 10.50 €
• Hearing aids rehabilitati...
   Price 12.50 €
• Far-advanced otosclerosis...
   Price 10.50 €
• «Less is more»: A new con...
   Price 14.00 €
• Transsexualism: From diag...
   Price 10.50 €
• Vertebro and cranio veino...
   Price 14.00 €
• Necrotizing external otit...
   Price 10.50 €
• Induction chemotherapy an...
   Price 10.50 €
• Post-traumatic otoscleros...
   Price 8.50 €
• Treatment of severe epist...
   Price 5.50 €
• Larynx manipulation....
   Price 5.50 €
• Termino-terminal hypoglos...
   Price 10.50 €
• These lesions of the voca...
   Price 10.50 €
• Pyogenic granuloma of the...
   Price 8.50 €
• Schwannoma of the tongue:...
   Price 5.50 €
• Hearing aid : practical a...
   Price 10.50 €
• Exploration of the otolit...
   Price 10.50 €
• Patient preference survey...
   Price 10.50 €
• A survey of current wound...
   Price 5.50 €
• A study of consonant inte...
   Price 10.50 €
• Otomycosis: Clinical and ...
   Price 5.50 €
• Paranasal sinus mucoceles...
   Price 14.00 €
• A detailed examination of...
   Price 10.50 €

Total Order 366.50 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 3 - 2014 o

CANCER

Sentinel lymph node biopsy in head and neck melano­ma: A single institution analysis


Authors : Penicaud M, Cammilleri S, Giorgi R, Grob JJ, Taïeb D, Giovanni A, Dessi P, Fakhry N. (Marseille)

Ref. : Rev Laryngol Otol Rhinol. 2014;135,3:115-120.

Article published in english
Downloadable PDF document english



Summary : Introduction: The aim of our study was to analyze a series of patients from our institution who underwent surgery for head and neck cutaneous melanoma and who received sentinel lymph node biopsy (SLNB). Material and methods: A single-center observational cohort of 120 head and neck melanoma patients was investigated from 2002 to 2011. Results: Among the 107 patients (89.2%) with lymph node identified during lympho­scinti­graphy, at least one node was collected and analyzed in 96 patients (90.6%). A positive sentinel lymph node was found in 9.4% of patients. Our data showed higher failure rate of lymphoscintigraphic identification (11.7%), lower rate of SLN posi­ti­vity (9.4%), and higher false-negative rate of SLNB (24.1%) than the usual figures established for malignant mela­no­mas in other locations. After a mean follow-up of 38.1 months, the disease-free survival (DFS) rate in the positive SLN group was 53% vs 75% for the negative SLN after 2 years of follow-up and 53% vs 48% after 5 years (p= 0.44). Con­clu­sion: The comple­xity of lymphatic drainage and the ana­tomy of the cervical region probably accounts for a speci­fi­ci­ties which result in a lower predictive value of SLNB in head and neck melanoma than in MM in other locations.

Price : 15.00 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE